Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1327, 2002-01, pp. : 13-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
IFN- -1b increases sVCAM-1 levels in primary progressive MS
Inpharma, Vol. 1, Iss. 1474, 2005-01 ,pp. :
Access to resources
Recommend
IFN- -1a, IFN- -1b, glatiramer acetate not warranted in MS
Inpharma, Vol. 1, Iss. 1462, 2004-01 ,pp. :
IFN- -1a, IFN- -1b, glatiramer acetate not warranted in MS
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 465, 2004-01 ,pp. :
Management of Secondary-Progressive Multiple Sclerosis
CNS Drugs, Vol. 18, Iss. 10, 2004-01 ,pp. :
IFN- -1b has greater bioactivity than IFN- -1a in MS?
Inpharma, Vol. 1, Iss. 1245, 2000-01 ,pp. :